Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma.
Forschner A, Sinnberg T, Mroz G, Schroeder C, Reinert CP, Gatidis S, Bitzer M, Eigentler T, Garbe C, Niessner H, Röcken M, Roggia C, Armeanu-Ebinger S, Riess O, Mattern S, Nann D, Bonzheim I.
Forschner A, et al. Among authors: mroz g.
Front Oncol. 2021 Mar 1;11:643156. doi: 10.3389/fonc.2021.643156. eCollection 2021.
Front Oncol. 2021.
PMID: 33732653
Free PMC article.